In Brazil, the epidemiology and care pathways of patients with inflammatory bowel disease (IBD) are poorly documented. Mapping the patient journey is key to identifying gaps and informing health policies. This study explores the Second Journey of IBD patients in Brazil and compares the findings with those from the First Journey. Two cross-sectional online surveys were conducted in 2017 and 2023 with adults diagnosed with IBD. The questionnaire addressed challenges in diagnosis, treatment, and disease impacts. Comparisons between survey waves were performed using logistic regression models adjusted for sex, age, and region, with results presented as adjusted absolute differences in prevalence and 95% confidence intervals. In the Second Journey (n = 2634), most participants were women (72.9%), aged 35–54 years (50.8%), and Crohn’s disease was the most common diagnosis (58.7%). Compared to the First Journey (n = 3549), a lower proportion of patients were diagnosed within one year of symptom onset (58.8% vs. 53.8%), corresponding to an adjusted difference of -3.5% percentage points (p.p.) (95% CI -6.1; -1.0). The proportion of patients using biological therapies was higher (40.6% vs. 60.9%), as was attendance at multidisciplinary clinics (8.0% vs. 10.0%). A higher proportion of patients reported being satisfied with treatment (30.2% vs. 41.6%; +10.4 p.p., 95% CI 8.0; 12.9). Fatigue was the most frequent symptom, even during remission. The Second Journey highlights the persistent impact of IBD on daily life. Gaps in multidisciplinary care and patient experience remain, emphasizing the need for more comprehensive care strategies.
Machado et al. (Tue,) studied this question.